Aptevo Therapeutics (NASDAQ:APVO) Issues Quarterly Earnings Results

Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported ($5.19) earnings per share for the quarter, missing the consensus estimate of ($3.71) by ($1.48), FiscalAI reports.

Aptevo Therapeutics Price Performance

Shares of APVO stock opened at $0.59 on Monday. The company’s fifty day simple moving average is $1.59 and its two-hundred day simple moving average is $4.01. Aptevo Therapeutics has a 52 week low of $0.59 and a 52 week high of $25.74. The stock has a market cap of $1.08 million, a P/E ratio of -0.01 and a beta of 1.65.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Aptevo Therapeutics currently has a consensus rating of “Sell”.

Read Our Latest Stock Analysis on Aptevo Therapeutics

About Aptevo Therapeutics

(Get Free Report)

Aptevo Therapeutics Inc. is a biotechnology company developing targeted immunotherapies for cancer and other serious diseases. The company is headquartered in Seattle, Washington, and was established in 2016 as a spin-off from Emergent BioSolutions. Aptevo’s research is based primarily on its ADAPTIR and ADAPTIR-FLEX antibody platforms, which are designed to create bispecific immune-cell engagers. These therapies are intended to connect immune cells with cancer cells or activate immune pathways to produce a targeted response.

Read More

Earnings History for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.